Effects of controlled-release alpha lipoic acid in lean, nondiabetic patients with polycystic ovary syndrome.

ABSTRACT:

Background

The purpose of this study was to determine whether a preparation of controlled-release alpha lipoic acid (CRLA) influences features of the polycystic ovary syndrome (PCOS).

Methods

We administered CRLA 600 mg twice daily for 16 weeks to six lean, nondiabetic patients with PCOS. Insulin sensitivity was measured by the euglycemic, hyperinsulinemic clamp. Plasma lipids were measured by vertical ultracentrifugation. Oxidative stress markers were measured in serum.

Results

At the end of 16 weeks of CRLA treatment, there was a 13.5% improvement in insulin sensitivity as determined by the euglycemic, hyperinsulinemic clamp (p < .03). There was also a lowering of triglyceride levels (p < .04) and a shift in the distribution of low-density lipoprotein (LDL) particle

SUBMITTER: Masharani U 

PROVIDER: S-EPMC2864173 | biostudies-literature | 2010 Mar

REPOSITORIES: biostudies-literature